10 research outputs found
Principios que informarán el nuevo Código Procesal Civil de la República de El Salvador y las perspectivas de aplicación por los operadores de la Zona Oriental.
Analizar los principios que regirán el nuevo proceso civil y los establecidos en el Código Procesal Civil vigente. La investigación es exploratoria, porque el tema objeto de estudio radica en el documento de bases minuciosas y detalladas para el nuevo Código Procesal Civil salvadoreño, el que pocas personas conocen, del cual poco se ha hablado y sólo existen algunos comentarios al respecto. Además lo que se persigue es conocer la opinión que merece la elaboración de un nuevo código, los principios que lo inspiran, ventajas del mismo y la forma en que se aplicará. Los estudios exploratorios se efectúan, normalmente, cuando el objetivo es examinar un tema o problema de investigación poco estudiado o que no ha sido abordado antes. Esta investigación se complementará con investigación documental e investigación de campo; porque se ha recogido y consultado diversa información de leyes y doctrina extranjera y nacional, que ha servido para el planteamiento del problema y la elaboración del marco teórico, así como para adoptar teorías y corrientes que han dependido de la información obtenida según las necesidades planteadas. Investigación es de campo, porque los objetivos y las hipótesis planteadas se probarán o no, mediante el estudio práctico que realizará como resultado de la aplicación de los respectivos instrumentos. Las conclusiones a que se llegaron están basadas en que los principios procesales como rectores del nuevo proceso civil, darán una connotación diferente al proceso civil, siendo éste moderno y sistematizado, donde básicamente será un proceso garantista, debido a que existirán en el código, principios constitucionales que serán directrices, ayudando con esto a establecer un verdadero debido proceso en el ámbito procesal civil, siendo de vital importancia una capacitación previa, del nuevo proceso antes de su instauración, ya que el conocimiento de la normativa, generará una mejor aplicación de la ley, por parte de los operadores de justicia buscando la seguridad jurídica, dado que los intereses de los particulares estarán respaldados por un proceso garantista, transparente, democrático y eficient
Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
BACKGROUND AND AIMS: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. METHODS: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. RESULTS: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. CONCLUSIONS: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.status: publishe
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
investigators - Portugal: Mafalda Bourbon (NLI), Ana C. Alves, Ana M. Medeiros (Unidade I&D, Grupo de Investigação Cardiovascular, Dept. de Promoção da Saúde e Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa; University of Lisboa, Faculty of Sciences, BioISI – Biosystems & Integrative Sciences Institute, Lisboa).Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries.Highlights: The EAS FHSC is an international initiative involving a network of investigators interested in FH from around 70 countries; Information on FH prevalence is lacking in most countries; where available, data tend to align with contemporary estimates; FH diagnosis and management varies widely across countries, with overall suboptimal identification and under-treatment; In most countries diagnosis primarily relies on DLCN criteria, and less frequently on Simon Broom or MEDPED; Therapy for FH is not universally reimbursed, and criteria vary across countries. Access to PCSK9i and apheresis is limited.info:eu-repo/semantics/publishedVersio
Overview of the current status of familial hypercholesterolaemia care in over 60 countries: The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries